Business
Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions
Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific
About this update from Zealand Pharma A/s
[{"type":"text","content":"Press release – No. 10 / 2026Zealand Pharma to Present Data atthe American Diabetes Association's 2026 Scientific SessionsLate-breaking Phase 2 ZUPREME-1 data on petrelintide to be featured as ePoster Theater presentation and poster sessionsCopenhagen, Denmark, May 27, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that data from its obesity and metabolic health pipeline will be presented at the 2026 Scientific Sessions of the American Diabetes Association® (ADA) taking place June 5–8, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. \"The ADA’s Scientific Sessions is one of the most significant global scientific platforms highlighting innovation in metabolic health, and we look forward to sharing additional data from our obesity pipeline with the scientific community in New Orleans,\" said David Kendall, MD, Chief Medical Officer of Zealand Pharma. The presentations will highlight Zealand Pharma's continued progress in advancing innovative treatment options for people living with overweight and obesity, leveraging the Company's more than 25 years of expertise in peptide research and development, including Phase 2 results from the ZUPREME-1 trial of the amylin analog, petrelintide, being developed in collaboration with Roche. Notably, the ZUPREME-1 data has been selected as part of the ADA Official Press Program.Amylin Symposium Zealand Pharma encourages participants to attend the following symposium, which will highlight the evolving role of amylin in the treatment of diabetes and obesity:Symposium: Amylin as a Novel Diabetes and Obesity TherapyModerator: W. Timothy Garvey, MDSession: CT-SY23-1.5; Friday June 5, 2026, from 3:45-5:15 p.m. CT in Great Hall A (Level 1)Petrelintide Presentation DetailsePoster Theater PresentationMain Session: Advances in Clinical Therapeutics for Type 1 and Type 2 DiabetesePoster Theater Presentation: Petrelintide, a Human Amylin Analog for the Treatment of Obesity: Efficacy and Safety from the Phase 2 Trial, ZUPREME 1Presenter: W. Timothy Garvey, MDSession: 3083-LB; Saturday, June 6, 2026, from 1:30-1:40 p.m. CT in ePoster Theater A (Halls B1-C)Petrelintide Poster DetailsBoard NumberTitlePresenterDate/Time3083-LBPetrelintide, a Human Amylin Analog for the Treatment...